University of Oxford

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private

Established: 1096-01-01

Employees: 10K

Market Cap: -

Website: http://www.ox.ac.uk

Clinical Trials

Reproductive Endocrinology Oxford Study (RepOx)

Recruiting

Conditions: Polycystic Ovary Syndrome

Interventions: Other: No intervention

First Posted Date: 2022-01-04

Last Posted Date: 2022-01-04

Lead Sponsor: University of Oxford

Target Recruit Count: 1175

Registration Number: NCT05177562

Locations: 🇬🇧
Nuffield Department Women's and Reproductive Health, Oxford, Oxfordshire, United Kingdom

AsseSSing Impact in pSoriatic Treatment

Conditions: Psoriatic Arthritis

Interventions: Other: Questionnaire

First Posted Date: 2021-12-28

Last Posted Date: 2022-05-19

Lead Sponsor: University of Oxford

Target Recruit Count: 500

Registration Number: NCT05171270

Locations: 🇪🇸
Complejo Universitario de a Coruña, Coruña, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇩🇪
Universitatsklinik Frankfurt, Frankfurt, Germany

and more 18 locations

The Oxford Risk Factors And Non-Invasive Imaging Study

Recruiting

Conditions: Cardiovascular Diseases
Cardiovascular Risk Factors

First Posted Date: 2021-12-23

Last Posted Date: 2024-12-11

Lead Sponsor: University of Oxford

Target Recruit Count: 250000

Registration Number: NCT05169333

Locations: 🇬🇧
Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
🇺🇸
NIH National Heart, Lunch, and Blood Institute, Bethesda, Maryland, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 34 locations

Effectiveness of 'Taking it Further' (TiF) Programme

Not Applicable

Completed

Conditions: Mindfulness

Interventions: Behavioral: Taking it Further

First Posted Date: 2021-12-13

Last Posted Date: 2022-01-13

Lead Sponsor: University of Oxford

Target Recruit Count: 168

Registration Number: NCT05154266

Locations: 🇬🇧
University of Oxford, Oxford, Oxfordshire, United Kingdom

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Phase 1

Active, not recruiting

Conditions: Malaria

Interventions: Biological: R21/Matrix-M - single vial formulation
Biological: Licensed vaccine - Measles-rubella
Biological: R21/Matrix-M - two vial formulation
Biological: Licensed vaccine - Pentavalent (diphtheria, tetanus, pertussis, hepatitis B and Hib)
Biological: Licensed vaccine - Yellow fever
Biological: Licensed vaccine - Oral Polio Vaccine (OPV)
Biological: Licensed vaccine - Rotavirus
Biological: Licensed vaccine - Pneumococcal vaccine
Biological: Licensed vaccine - Inactivated Polio Vaccine (IPV)

First Posted Date: 2021-12-13

Last Posted Date: 2024-05-16

Lead Sponsor: University of Oxford

Target Recruit Count: 590

Registration Number: NCT05155579

Locations: 🇬🇧
CCVTM, University of Oxford, Oxford, United Kingdom
🇲🇱
Malaria Research & Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy and Dentistry, University of Sciences Techniques and Technologies of Bamako, Bamako, Mali

LEONIDaS Caregivers Study

Withdrawn

Conditions: Anxiety
Depression
Dravet Syndrome

Interventions: Other: Multiple

First Posted Date: 2021-12-01

Last Posted Date: 2023-12-14

Lead Sponsor: University of Oxford

Registration Number: NCT05140122

Study to Compare Feasibility of 1-step Injectable Artesunate vs. Conventional 2-step Injectable Artesunate

Phase 2

Completed

Conditions: Severe Malaria

Interventions: Drug: Argesun 60mg (1 step parenteral artesunate)
Drug: Artesun 60mg (2-step parenteral artesunate)

First Posted Date: 2021-12-01

Last Posted Date: 2024-03-15

Lead Sponsor: University of Oxford

Target Recruit Count: 200

Registration Number: NCT05140278

Locations: 🇨🇩
KIMORU (KIMORU /ESP Research Center), Kinshasa, Congo, The Democratic Republic of the

vHDU Phase 5: Impact of an Ambulatory Monitoring System on Deterioration Detection and Clinical Outcomes

Not Applicable

Recruiting

Conditions: Surgery
Deterioration, Clinical

Interventions: Device: Ambulatory monitoring system
Device: Active alerting system

First Posted Date: 2021-11-12

Last Posted Date: 2024-03-07

Lead Sponsor: University of Oxford

Target Recruit Count: 120

Registration Number: NCT05118477

Locations: 🇬🇧
Oxford University Hospitals Trust, Oxford, Oxfordshire, United Kingdom

IMPase in Treatment-resistant Depression

Phase 1

Recruiting

Conditions: Depressive Disorder, Treatment-Resistant

Interventions: Drug: Placebo
Drug: Ebselen

First Posted Date: 2021-11-11

Last Posted Date: 2023-07-06

Lead Sponsor: University of Oxford

Target Recruit Count: 50

Registration Number: NCT05117710

Locations: 🇬🇧
Neurosciences Building, Dept. Psychiatry, Warneford Hospital, Oxford, Oxfordshire, United Kingdom

Windows Trial of INsulin-like Growth Factor Neutralising Antibody Xentuzumab in MEN Scheduled for Radical Prostatectomy (WINGMEN)

Early Phase 1

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Drug: Xentuzumab

First Posted Date: 2021-11-08

Last Posted Date: 2023-04-21

Lead Sponsor: University of Oxford

Target Recruit Count: 27

Registration Number: NCT05110495

Locations: 🇬🇧
Churchill Hospital, Oxford University Hospitals, Oxford, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy